{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028632","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.470510+00:00","generated_at":"2026-06-11T13:22:01.541645+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sanara MedTech Q2 revenue up 63% to $15.8M; acquires collagen assets to cut royalties","bullets":["Q2 2023 net revenues $15.8M (+63% YoY); net loss $1.9M vs net income $0.8M in prior year.","Completed post-quarter acquisition of collagen-related assets including CellerateRX Surgical and HYCOL.","Annual royalties on collagen products were $1.8M in 2022; acquisition expected to eliminate those payments.","Products sold in over 950 facilities and contracted in 3,000+ hospitals/ASCs as of June 30.","Loss before income taxes improved to $1.9M from $3.4M in Q2 2022 due to slower expense growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028632","json":"https://secwatch.observer/filing/0001493152-23-028632.json","markdown":"https://secwatch.observer/filing/0001493152-23-028632.md","text":"https://secwatch.observer/filing/0001493152-23-028632.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315223028632/0001493152-23-028632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315223028632/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:22:01.541645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67b9197cfb25e884cac23acf3dfb0ffe3cf02c9e","claim":"Sanara MedTech Inc. reported the three months ended June 30, 2022 results: revenue $9.7 million, net income net income of $0.8 million.","evidence_excerpt":"wound care uses and five trademarks. Sales Analysis The Company generated net revenues of $15.8 million for the three months ended June 30, 2023, compared to net revenues of $9.7 million for the three months ended June 30, 2022, a 63% increase from the prior year period. The higher net revenues for the three months ended June 30, 2023 were primarily due to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315223028632/0001493152-23-028632-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2022"},{"label":"Revenue","value":"$9.7 million"},{"label":"Net income","value":"net income of $0.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7cd7af3f22e22de0807aa4f065e10c6f3db5f958","claim":"Sanara MedTech Inc. reported the quarter ended June 30, 2023 results: revenue $15.8 million, net income net loss of $1.9 million.","evidence_excerpt":"The Company generated net revenues of $15.8 million for the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315223028632/0001493152-23-028632-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$15.8 million"},{"label":"Net income","value":"net loss of $1.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}